A Phase I Study to Evaluate Single and Multiple (Seven) Oral Doses of SRT2104 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs SRT 2104 (Primary)
- Indications Chronic obstructive pulmonary disease; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 04 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 04 Jun 2010 Actual patient number (41) added as reported by ClinicalTrials.gov.